Postoperative radiation therapy for primary vs. recurrent squamous cell carcinoma of the head and neck: Results of a comparative analysis

Citation
Wf. Regine et al., Postoperative radiation therapy for primary vs. recurrent squamous cell carcinoma of the head and neck: Results of a comparative analysis, HEAD NECK, 21(6), 1999, pp. 554-559
Citations number
35
Categorie Soggetti
Otolaryngology
Journal title
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
ISSN journal
10433074 → ACNP
Volume
21
Issue
6
Year of publication
1999
Pages
554 - 559
Database
ISI
SICI code
1043-3074(199909)21:6<554:PRTFPV>2.0.ZU;2-Z
Abstract
Background. There is little literature comparatively evaluating the results of postoperative radiation therapy (RT) for patients with squamous cell ca rcinoma (SCC) of the head and neck treated for primary versus recurrent dis ease. Methods. Between 1981 and 1993, 174 patients with SCC of the head and neck, 143 with primary and 31 with recurrent disease, were treated with standard postoperative RT. Results. Patients treated for primary disease had 5-year local-regional con trol (LRC) and disease-specific survival (DSS) rates of 69% and 54%, respec tively, as compared with 46% and 32%, respectively, for patients treated fo r recurrent disease (P = 0.03 and 0.04, respectively). On multivariate anal ysis, only tumor type (primary vs recurrent) significantly influenced LRC ( P = 0.003) and only primary tumor site (oral cavity vs nonoral cavity) sign ificantly influenced DSS (P = 0.04). Among the patients treated for recurre nt disease, site of recurrence (undissected vs dissected tissue) significan tly influenced both LRC and DSS (P= 0.008 and 0.001, respectively). Conclusions. Patients with recurrent SCC of the head and neck do poorly as compared with those with primary disease when treated with standard postope rative RT, particularly when the recurrence is within previously dissected tissue. This patient group should be targeted for alternative treatment str ategies. (C) 1999 John Wiley & Sons, Inc.